three years of 503B threads, summarised so you do not have to read them
three years of 503B threads, summarised so you do not have to read them. I have gone back and forth on this for months. A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available. A 503A…
if a clinic will not name the facility, that is your answer
if a clinic will not name the facility, that is your answer
This is the distinction the whole board runs on. Everything else follows from it.
shortage status changes and the whole arrangement changes with it
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
the price difference is mostly the intake, not the vial
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
Same view.
Agreed — and the follow-up question is what the beyond-use date is based on.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
ask which facility, then ask for their testing
the pharmacy and the prescriber are two separate questions